Evaluation Study of RDTs Detecting Antibodies Against HCV

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1710 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-09-21

Study Completion Date

2019-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to evaluate 13 different HCV RDTs (10 on-market, 3 under development) for their diagnostic performance and operational characteristics in archived EDTA plasma samples, originating from patients from different geographical regions (Nigeria, Georgia, Cambodia, Belgium) and with or without HIV co-infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity)

NCT04453280

COVID SARS-CoV-2

COMPLETED

Study of the Role of Dendritic Cells in the Recurrence of Hepatitis C After Liver Transplantation. Analysis of Hepatitis C Virus (HCV) Quasispecies Evolution.

NCT00213707

HCV Infection

UNKNOWN

COVID-19 Immune Repertoire Sequencing

NCT04368143

COVID SARS-CoV 2 Corona Virus Infection +2 more

COMPLETED

Hepatitis C Virus in Neutrophil Granulocyte Progenitor Cells

NCT02545387

Chronic Hepatitis C

WITHDRAWN

Bartonella in Liver Transplant Patients

NCT02595710

Cryptogenic Cirrhosis Cryptogenic Chronic Hepatitis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background and rationale:

Screening of past exposure to Hepatitis C Virus (HCV) infection is done by detection of HCV specific antibodies. In Low and Middle Income Countries (LMICs), where equipped laboratories and trained staff are limited, Rapid Diagnostic Tests (RDTs) are widely used for HCV screening. Although many RDTs are available on the market, only some of them received CE-IVD marking and only two have been validated by WHO Pre-Qualification (PQ). More quality-assured tests are needed to establish effective screening programmes in LMICs.

Furthermore, an important research gap is the lack of studies on the impact of HIV positivity on RDT performance, as it is estimated that 2-15% of people living with HIV are co-infected with HCV.

The evaluation of RDT performance on clinical samples collected in different geographic regions as well as from HIV co-infected individuals, would allow to identify tests with a performance meeting or having the potential to meet WHO quality standards.

Concept:

This is a multicenter laboratory evaluation study using archived, frozen plasma samples.

Sensitivity and specificity of RDTs will be measured against a composite reference standard that consists of two WHO prequalified Enzyme Immunoassays (EIAs) (Murex Anti-HCV EIA version 4.0, Fujirebio Innotest HCV Ab IV) and a Line Immunoassay (LIA) (MP Diagnostics HCV blot 3.0). Samples are assigned as anti-HCV negative or anti-HCV positive based on the results of all three assays.

RDT results will be read by three independent readers to evaluate inter-reader variability (differences in visual interpretation, i.e. presence or absence of test and control line).

For each RDT, two independently produced lots will be tested for each sample to assess lot-to-lot variability (differences in RDT result for the same sample). Furthermore, rate of invalid runs will be assessed and a technical appraisal is completed for each RDT.

Primary objective:

1.1 Evaluation of sensitivity and specificity of anti-HCV RDTs in archived plasma samples, collected from HCV-infected and HCV-uninfected individuals not co-infected with HIV, measured against the composite reference standard composed of two Enzyme Immunoassays (EIAs) and a Line Immunoassay (LIA).

1.2 Evaluation of sensitivity and specificity of anti-HCV RDTs in archived plasma samples, collected from HCV-infected and HCV-uninfected individuals who are all co-infected with HIV, measured against the composite reference standard composed of two EIAs and a LIA.

Secondary objectives:

2.1 Evaluation of sensitivity and specificity of anti-HCV RDTs in archived plasma samples, collected from HCV-infected and HCV-uninfected individuals, both co-infected and not with HIV, measured against the composite reference standard composed of two EIAs and a LIA.

2.2 Evaluation of operational characteristics of anti-HCV RDTs: inter-reader variability; lot-to-lot variability; rate of invalid runs 2.3 Technical appraisal of each RDT product per manufacturer

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HCV-only infected

Archived frozen plasma samples from individuals that were characterised to be HCV-antibody positive or HCV-antibody negative ("HCV-only infected"). These samples are characterised for their HIV status (negative).

13 Rapid Diagnostic Tests and reference tests

Intervention Type DIAGNOSTIC_TEST

Rapid diagnostic tests:

1. HCV antibody test (under development); bioLytical Laboratories
2. DPP® HCV (under development); Chembio Diagnostic Systems
3. HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise
4. Rapid Anti-HCV Test; InTec
5. First Response HCV Card Test; Premire Medical Corporation
6. Signal HCV Ver 3.0; Arkray healthcare
7. TRI DOT HCV; J. Mitra \& Co
8. Triplex HIV, HCV, HBsAg; Biosynex SA
9. Standard Q HCV Ab; SD Biosensor
10. HCV Hepatitis Virus Antibody Test; Artron Laboratories
11. SD Bioline HCV; Abbott Diagnostics
12. OraQuick HCV; OraSure
13. Care Start HCV Rapid Test (under development); Access Bio

Reference tests:

Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV

Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0

HCV/HIV co-infected

Archived frozen plasma samples from HCV-positive or HCV-negative individuals who are HIV infected ("HCV/HIV co-infected").

13 Rapid Diagnostic Tests and reference tests

Intervention Type DIAGNOSTIC_TEST

Rapid diagnostic tests:

1. HCV antibody test (under development); bioLytical Laboratories
2. DPP® HCV (under development); Chembio Diagnostic Systems
3. HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise
4. Rapid Anti-HCV Test; InTec
5. First Response HCV Card Test; Premire Medical Corporation
6. Signal HCV Ver 3.0; Arkray healthcare
7. TRI DOT HCV; J. Mitra \& Co
8. Triplex HIV, HCV, HBsAg; Biosynex SA
9. Standard Q HCV Ab; SD Biosensor
10. HCV Hepatitis Virus Antibody Test; Artron Laboratories
11. SD Bioline HCV; Abbott Diagnostics
12. OraQuick HCV; OraSure
13. Care Start HCV Rapid Test (under development); Access Bio

Reference tests:

Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV

Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

13 Rapid Diagnostic Tests and reference tests

Rapid diagnostic tests:

1. HCV antibody test (under development); bioLytical Laboratories
2. DPP® HCV (under development); Chembio Diagnostic Systems
3. HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise
4. Rapid Anti-HCV Test; InTec
5. First Response HCV Card Test; Premire Medical Corporation
6. Signal HCV Ver 3.0; Arkray healthcare
7. TRI DOT HCV; J. Mitra \& Co
8. Triplex HIV, HCV, HBsAg; Biosynex SA
9. Standard Q HCV Ab; SD Biosensor
10. HCV Hepatitis Virus Antibody Test; Artron Laboratories
11. SD Bioline HCV; Abbott Diagnostics
12. OraQuick HCV; OraSure
13. Care Start HCV Rapid Test (under development); Access Bio

Reference tests:

Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV

Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-hemolytic plasma samples with EDTA used as anticoagulant
* Sample were frozen at -20°C or lower on the day of processing and stored at -20°C or lower until they are used in this study
* Samples pre-characterized for, HCV, HIV serology status using assays routinely used at the sites and approved for diagnostic use by a local health authority. If available, samples should also be characterized for HBV status.
* Samples taken from subjects aged ≥18 years
* Availability of informed consent to use the sample in future research